News and Announcements
Juggle Street Passes 20,000 Users, Raises 540K & Launches New $1m Capital Raise
- Published July 12, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Juggle Street’s exponential growth passes 20,000 users, new $1.0M capital raising to fund “massive growth” phase, launches first Intelligent Messaging Bot.
In May Juggle Street passed 20,000 users in Sydney, the first 10,000 took 2 years and the second 10,000 just 8 months. The company raised $540K of equity in FY17 and converted $500K of convertible notes from FY16. Now seeking $1.0M to build up internal skills and capabilities to evolve into a “Growth Engineering” company to move into a massive growth phase. Juggle Bot, the companies first series of intelligent messaging bots will be released this month.
ABOUT JUGGLE STREET
Juggle Street is an on-demand job platform for babysitting, nannying and after-school care; connecting busy working families with local helpers. It offers a unique solution to an ongoing pain-point felt by 2.1M working mothers in Australia.
Juggle Street launched in Nov 2014 in Sydney, has raised $900K to date and achieved product-market fit. Juggle Street’s disruptive business model and technology offers an affordable, scalable neighbourhood marketplace superior to the competition. Juggle Street founder & CEO is a successful serial entrepreneur. You will be investing in custom built technology and a tight and professional team.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
